Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01468246 · ClinicalTrials.gov registry record
The Young Women's Breast Cancer Study
A clinical trial of Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- 1,302
- Enrollment target
- 13
- Study locations
NCT01468246 is a study of Breast Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 1,302 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (54% lower). The trial reports 13 study locations across 5 states.
The verdict
NCT01468246, a study of Breast Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- 1,302 participants
- Enrollment target
- 13
- Study locations
Study Summary
The investigators are conducting a longitudinal cohort study of young women with breast cancer. The investigators identify women age 40 and younger with newly-diagnosed breast cancer from academic and community healthcare institutions. After women consent to the study, they fill-out surveys and give blood samples, and the investigators collect tissue from their breast cancer tumor after it is removed. Women are surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of at least 10 years following diagnosis). The study investigates short and long-term disease and treatment issues, tumor biology and the relationship to patient outcomes, and psychosocial concerns at baseline and in follow-up among a cohort of young women who are newly-diagnosed with breast cancer.
Conditions Studied
Study Locations (13)
Massachusetts
- Beth-Israel Deaconess Medical Center - Boston
- Dana-Farber Cancer Institute - Boston
- Massachusetts General Hospital - Boston
- MGH/North Shore Cancer Center - Danvers
- Cape Cod Hospital - Hyannis
- Lowell General Hospital - Lowell
- DF/BWCC at Milford Regional Medical Center - Milford
- Newton-Wellesley Hospital - Newton
- South Shore Hospital - South Weymouth
Colorado
- University of Colorado Cancer Center - Aurora
Minnesota
- Mayo Clinic - Rochester
New Hampshire
- Dana-Farber/New Hampshire Oncology-Hematology - Londonderry
Ontario
- Sunnybrook Health Sciences Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,302 participants |
| Start Date | 2006-11 |
| Est. Completion | 2035-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01468246
The ClinicalTrials.gov registry entry for NCT01468246 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,302 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (54% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT01468246 reports 13 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Colorado, Minnesota.
Frequently Asked Questions
What is clinical trial NCT01468246 about?
NCT01468246 is a clinical study titled "The Young Women's Breast Cancer Study". The investigators are conducting a longitudinal cohort study of young women with breast cancer. The investigators identify women age 40 and younger with newly-diagnosed breast cancer from academic and community healthcare institutions. After women consent to the study, they fill-out surveys and give...
What is the current status of trial NCT01468246?
This trial is currently active not recruiting. The enrollment target is 1,302 participants. The study started on 2006-11. Estimated completion is 2035-01.
What conditions does trial NCT01468246 study?
This clinical trial studies the following conditions: Breast Cancer.
Who is sponsoring clinical trial NCT01468246?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01468246 being conducted?
This trial has 13 study locations across Colorado, Massachusetts, Minnesota, New Hampshire, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.